Pfizer Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER

PFIZER has one hundred and ninety-seven approved drugs.

There are fifty US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

Summary for Pfizer

US Patents:	50
Tradenames:	161
Ingredients:	131
NDAs:	197
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Drugs and US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	10,723,730*PED				Y
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	217439-004	Mar 7, 2024		RX	Yes	No
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-005	Jun 20, 2023		DISCN	Yes	No	8,012,976		Y	Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019		RX	Yes	No
Pfizer	LONITEN	minoxidil	TABLET;ORAL	018154-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-001	Nov 19, 1991		DISCN	Yes	No

Expired US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-002	Apr 6, 1982	3,591,564
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	7,842,699
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999	5,091,190
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994	4,612,008
Pfizer	ZINECARD	dexrazoxane hydrochloride	INJECTABLE;INJECTION	020212-001	May 26, 1995	4,275,063
Pfizer	DEPO-PROVERA	medroxyprogesterone acetate	INJECTABLE;INJECTION	012541-002	Approved Prior to Jan 1, 1982	4,038,389

Paragraph IV (Patent) Challenges for PFIZER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	4 mg and 8 mg		2012-10-31
	Injection	20 mg/mL, 2 mL and 5 mL vials		2004-07-26
	Capsules	5 mg and 10 mg		2005-06-21
	For Injection	500 mg/vial		2011-06-17
	Oral Suspension	100 mg/5 mL		2009-08-03
	Injection	2 mg/mL, 100 mL bag		2009-12-29
	Tablets	5 mg		2016-11-07
	Delayed-release Tablets	50 mg/0.2 mg		2009-06-29
	Extended-release Tablets	11 mg		2016-11-07
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Capsules	75 mg, 100 mg and 125 mg		2019-02-04
	Capsules	0.125 mg, 0.25 mg, and 0.5 mg		2014-05-01
	Tablets	600 mg		2005-12-21
	Injection	2 mg/mL, 300 mL bag		2009-09-01
	Tablets	1 g		2005-08-23
	Delayed-release Tablets	75 mg/0.2 mg		2008-11-28

International Patents for Pfizer Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2326650
Lithuania	C2170860
Israel	255224
Lithuania	2326621
Mexico	368464
European Patent Office	3310760

Supplementary Protection Certificates for Pfizer Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1746976	2017C/027	Belgium		PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
3077395	202440002	Slovenia		PRODUCT NAME: RITLECITINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1755/001-003; DATE OF NATIONAL AUTHORISATION: 20230915; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2767537	19C1071	France		PRODUCT NAME: TALAZOPARIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1377 20190624
1746976	LUC00026	Luxembourg		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pfizer
• Pfizer Global
• Pfizer Inc
• Pfizer Labs
• Pfizer Pharms